• 5 ADC Manufacturing Challenges You Need To Know
    5 ADC Manufacturing Challenges You Need To Know

    The unique targeting capabilities and promising clinical trial results of antibody-drug conjugates (ADCs) have made them an exciting and promising treatment in the fight against cancer. According to recent analysis, experts anticipate the ADC market to be worth $10 billion annually by 2025. However, despite this tremendous growth, drugmakers still face a number of challenges in the manufacturing process for ADCs. Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.

  • From Discovery To Development: GS Expression System For Next-Generation Biologics

    Compared to traditional antibody expression, where routine purification and analytical strategies have been established over the last few years, next-generation biologics have complex designs. If you are first in class or you have a very bespoke up- and downstream process, it also means you will have bigger hurdles to overcome when it comes to regulatory support and filing. At Lonza, these challenges are addressed with the GS™ expression platform.

  • Digging Into The Details: Commonly Asked Questions About Lonza’s XS And GS Expression Systems

    No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. Experts from Lonza answers questions about the proprietary expression platforms the company has assembled to rapidly generate high-producing cell lines for biological candidates.

  • How Pacira Pharma Is Working To Help Curb The Opioid Epidemic

    The most effective way to stop the epidemic of opioid dependence is to eliminate the use of these highly addictive drugs after surgery. This was the goal of Pacira Pharmaceuticals, a specialty pharmaceutical company focused on the development of non-opioid products for postsurgical pain control, when it developed its injectable suspension, EXPAREL®.

  • Early Implementation Of Quality By Design For Biological Product Development

    The idea of thinking in terms of “operational excellence” is a relatively new idea for the biopharmaceutical industry. The enormous uncertainty associated with bringing a biological drug product from discovery to approval almost precludes the thought of forward-thinking in terms of what makes a quality product, especially during early-stage development. However, extensive product knowledge is gathered during early development, and crucial decisions are made in terms moving the science forward to generate the data required to meet your business objectives.

More From Featured Articles


Drug Process Development Drug Process Development

Althea’s complete range of drug Process Development capabilities offers the tools to address your needs. We develop processes for producing small quantities of proteins for early testing or establish robust, reliable and scalable processes that enable a strong commercial advantage. Althea also provides access to a proprietary drug delivery platform, called Crystalomics® technology, for the development of alternative drug delivery formulations of second generation drug substances.

Combinatorial Synthesis Instrument Combinatorial Synthesis Instrument
MULTIBLOCK is an instrument used for multiple and combinatorial synthesis that has a teflon block, which holds 42 reactors, and
NetGenics ChemSymphony
NetGenics ChemSymphony is a suite of Java Bean components for the creation of Web-based applications that locate, visualize in 2D and 3D, annotate and save chemical structures. ChemSymphony enables the construction of a single desktop chemical information system, incorporating ChemSymphony components.
Screening Reagent Screening Reagent
The Pan-Enterovirus reagent has an atypical staining pattern in the cytoplasm that should appear speckled and
Chromatography System Chromatography System
The Ace Chromatography System uses prepacked columns and also offers four solvent delivery systems
Lab Coat Lab Coat
The ISO 9002 Certified Disposable SMS Lab Coat with knit collar and cuffs is strong, fluid-resistant, and breathable, and provides a mix of protection and comfort...
More Featured Products


CHI's Immunogenicity and Bioassay Summit 2016 October 26 - 28, 2016
Baltimore, MD
Biosimilars 2016 October 27 - 28, 2016
Washington, DC, DC
The Top Method Validation Mistakes – And How to Avoid Them November 2, 2016
1pm-2:30pm EST, Online Training
More Events....


The Top Method Validation Mistakes – And How to Avoid Them November 2, 2016
1pm-2:30pm EST, Online Training
Selecting a CMO/CDMO: 11 Best Practices For Sourcing The Right Partner November 9, 2016
1pm-2:30pm EST, Online Training
Preparing eCTD Submissions: A Step-By-Step Guide November 10, 2016
1pm-2:30pm EDT, Online Training
"Powering Up" Your GMP Training - Make Training Fun! November 16, 2016
1pm-2:30pm EST, Online Training
More Upcoming Courses